Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 1
2007 4
2008 5
2009 10
2010 10
2011 8
2012 12
2013 15
2014 13
2015 11
2016 15
2017 15
2018 14
2019 14
2020 27
2021 28
2022 14
2023 28
2024 19
2025 10
2026 23

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

267 results

Results by year

Filters applied: . Clear all
Page 1
Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.
Aronchik I, Kar S, Zhuang Y, Ahler E, Lai LP, Seshadri V, Yang YC, Bulle A, Menard M, Nayak B, Labrecque MP, Dilly J, Kim E, Jiang L, Yano J, Wasko UN, Helland C, Bredeson S, Garrick B, Gindin Y, Sickler B, Wei X, Seamon K, Jiang J, Lim KH, Holderfield M, Quintana E, Hegde A, Salman Z, Starodub A, Spira A, Park W, Hong DS, Barve M, Pelster M, Sommerhalder D, Punekar SR, Garrido-Laguna I, Wolpin BM, Maitra A, Gustafson WC, Kelsey S, Smith JAM, Lin KK, Aguirre AJ, Singh M. Aronchik I, et al. Among authors: wolpin bm. Nat Med. 2026 Aug 11. doi: 10.1038/s41591-026-04537-w. Online ahead of print. Nat Med. 2026. PMID: 42581230
Impact of vitamin D on the colon cancer immune microenvironment: results of a randomized clinical trial of preoperative vitamin D supplementation in patients with stage I-III colon cancer.
Dias Costa A, Kim S, Hong SC, Yuan C, Qi X, Zhang J, Bleday R, Goldberg J, Irani J, Melnitchouk N, Sicinska ET, Lowder KE, Thalappillil JS, Takashima Y, Väyrynen SA, Payne EM, Meyerhardt JA, Yurgelun MB, Abrams TA, Coleman EC, Fitzpatrick B, Ganser C, Metayer KA, Brais LK, Shivdasani RA, Wolpin BM, Hollis BW, Nowak JA, Ng K. Dias Costa A, et al. Among authors: wolpin bm. Cancer Discov. 2026 Jul 8:10.1158/2159-8290.CD-25-1574. doi: 10.1158/2159-8290.CD-25-1574. Online ahead of print. Cancer Discov. 2026. PMID: 42417469 Free PMC article.
Adherence to the Mediterranean diet and risk of pancreatic cancer: an analysis of 2.3 million participants in the Pooling Project of Prospective Studies of Diet and Cancer (DCPP).
Shen Q, Mobley C, Wang M, Ferrari P, Adami HO, Afshar N, Babic A, van den Brandt PA, Cheng E, Eliassen AH, Fung TT, Giovannucci EL, Hirabayashi M, Hou T, Huang BZ, Huang WY, Joshu CE, Kanehara R, Katzke V, Lacey JV Jr, Landry MJ, Larsson SC, Liao LM, Martinez ME, McCullough ML, Miller AB, Milne RL, Moore SC, Mucci LA, Naudin S, Prizment A, Park SY, Rohan TE, Riboli E, Robien K, Sandin S, Sawada N, Shams-White MM, Sinha R, Smith-Byrne K, Stampfer MJ, Stolzenberg-Solomon RZ, Um CY, Visvanathan K, Wang SS, Weiderpass E, White E, Willett WC, Wolk A, Wolpin BM, Yuan C, Smith-Warner SA, Genkinger JM. Shen Q, et al. Among authors: wolpin bm. Eur J Epidemiol. 2026 Jun 25. doi: 10.1007/s10654-026-01418-x. Online ahead of print. Eur J Epidemiol. 2026. PMID: 42348090
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.
O'Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, Hammel P, Cremolini C, Manji GA, Oberstein PE, Garrido-Laguna I, Springfeld C, Azad NS, Ueno M, Chui SY, Zhang Y, Patel H, Lee Y, Salman Z, Wolpin BM; RASolute 302 Trial Investigators. O'Reilly EM, et al. Among authors: wolpin bm. N Engl J Med. 2026 Jul 23;395(4):325-337. doi: 10.1056/NEJMoa2605555. Epub 2026 May 31. N Engl J Med. 2026. PMID: 42223072 Clinical Trial.
Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models.
Antwi SO, Coombes BJ, Carlson EE, Larson NB, Rabe KG, Atkinson HJ, Majumder S, Bamlet WR, Schaid DJ, Zhong J, McKean D, Arslan AA, Beane Freeman LE, Bracci PM, Canzian F, Truong T, Atkins J, Du M, Gallinger S, Goodman PJ, Katzke V, Campa D, Kooperberg C, Le Marchand L, Neale RE, Patel AV, Wactawski-Wende J, Perdomo S, Shu XO, Visvanathan K, Van Den Eeden SK, White E, Zheng W, Albanes D, Andreotti G, Brennan P, Chanock SJ, Chen Y, Darst B, Ferrari P, Giovannucci EL, Goggins M, Haiman C, Hassan M, Hung RJ, Jones MR, Kraft P, Malats N, Moore SC, Ng K, Peters U, Porta M, Rothman N, Sánchez MJ, Sesso HD, Silverman DT, Southey MC, Milne RL, Um CY, Yu H, Yuan C; MAYO-RGC Project Generation; Regeneron Genetics Center; Risch HA, Wolpin BM, Stolzenberg-Solomon RZ, Klein AP, Amundadottir LT, Oberg AL. Antwi SO, et al. Among authors: wolpin bm. NPJ Precis Oncol. 2026 May 27. doi: 10.1038/s41698-026-01479-x. Online ahead of print. NPJ Precis Oncol. 2026. PMID: 42203843 Free article.
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.
Perez KJ, Dias Costa A, Jordan A, Karasic TB, Elganainy D, Kim S, Yuan C, Gui DY, Tan R, Hong SC, Wang X, Cristea S, Coleman E, Truitt M, Oh TG, Zheng H, Furniss CS, Brais L, Bird A, Remland J, Gocheva V, Thalappillil JS, Anderson M, Cleary JM, Enzinger A, Giannakis M, Ng K, Rubinson DA, Schlechter B, Surana R, Singh H, Abrams T, Teitelbaum U, Izgur N, Allen E, Winter PS, Raghavan S, Yeh JJ, Von Hoff D, Liddle C, Downes M, Evans RM, O'Dwyer P, Aguirre A, Nowak JA, Wolpin BM. Perez KJ, et al. Among authors: wolpin bm. Nat Cancer. 2026 Jun;7(6):928-943. doi: 10.1038/s43018-026-01165-8. Epub 2026 May 25. Nat Cancer. 2026. PMID: 42185478 Free PMC article. Clinical Trial.
Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer.
Kureshi CTS, Walsh MJ, Kureshi R, Cardot-Ruffino V, Agardy DA, Ali LR, Dougan JM, Qiang L, Shen J, Zuo C, Lenehan PJ, Wang SJ, Chang E, Remland J, Brais L, Clancy TE, Cleary JM, Hornick JL, Huffman BM, Mancias JD, Molina G, Fairweather M, Nowak JA, Perez KJ, Rubinson DA, Slater S, van Dams R, Wang J, Wolpin BM, Zhao L, Barrientos K, Novosiadly R, Broz M, Singh H, Dougan M, Dougan SK. Kureshi CTS, et al. Among authors: wolpin bm. Cancer Cell. 2026 Jul 13;44(7):1381-1400.e9. doi: 10.1016/j.ccell.2026.04.005. Epub 2026 May 7. Cancer Cell. 2026. PMID: 42102812 Free PMC article.
Disrupted molecular glue complex drives RAS inhibitor resistance.
Sang B, Ye LF, Fu Z, Pourfarjam Y, Cuevas-Navarro A, Fan S, Hu F, Washington A, Rodriguez DJ, Vides A, Kar S, Ahler E, Lin KK, Hegde A, Smith JAM, Wolpin BM, Punekar SR, Spira AI, Garrido-Laguna I, Hong DS, Dar AC, Yaeger R, Arbour KC, Lito P. Sang B, et al. Among authors: wolpin bm. Cell. 2026 May 14;189(10):2918-2933.e17. doi: 10.1016/j.cell.2026.03.031. Epub 2026 May 5. Cell. 2026. PMID: 42092352 Free article.
267 results